ACADIA Pharmaceuticals Inc. ( (ACAD) ) has released its Q2 earnings. Here is a breakdown of the information ACADIA Pharmaceuticals Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for neurological and rare diseases. The company is known for its FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome.
In the second quarter of 2025, Acadia Pharmaceuticals reported a total revenue of $264.6 million, marking a 9% increase compared to the previous year. The company’s flagship products, NUPLAZID and DAYBUE, both showed significant sales growth, with NUPLAZID achieving a 7% increase and DAYBUE a 14% increase year-over-year.
Key financial highlights include the raising of the lower end of NUPLAZID’s net product sales guidance and the completion of enrollment for the COMPASS PWS Phase 3 study. The company also secured two major patent litigation victories, ensuring market exclusivity for NUPLAZID until 2030 and 2038, respectively. Additionally, Acadia has expanded its field force and made strategic executive appointments to bolster its rare disease franchise.
Despite the positive revenue growth, Acadia’s net income for the quarter was $26.7 million, down from $33.4 million in the same period last year, primarily due to a higher effective tax rate. The company’s cash and investments stood at $762 million at the end of the quarter.
Looking ahead, Acadia Pharmaceuticals remains focused on advancing its pipeline, with several Phase 2 and Phase 3 studies expected to commence in the coming years. The company is optimistic about its long-term growth potential, driven by its robust R&D strategy and continued commercial execution.